<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501680</url>
  </required_header>
  <id_info>
    <org_study_id>HAPinsulin</org_study_id>
    <nct_id>NCT03501680</nct_id>
  </id_info>
  <brief_title>Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.</brief_title>
  <acronym>HAPinsulin</acronym>
  <official_title>Randomized, Controlled, Open-label Trial of Intravenous Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Wenzhou Medical Univeristy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Wenzhou Medical Univeristy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the therapeutic efficacy of intensive insulin in
      patients with hypertriglyceridemia induced moderate/severe acute pancreatitis on the course
      and outcome of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertriglyceridemia-induced acute pancreatitis occurs in about 1-4% of the cases. It is the
      third leading cause of pancreatitis after biliary and alcoholic etiology.
      Hypertriglyceridemia can be caused by primary causes, lipid metabolism disorders and
      secondary causes.

      Hyperlipidemic pancreatitis can be provoked when triglyceride levels (TGL) exceed 11.3 mmol/l
      (1,000 mg/dl). Except for standard symptomatic treatment, plasmapheresis and insulin have
      been performed to rapidly reduce TGL and chylomicron levels in the blood.The therapeutic
      efficacy of intensive insulin, standard insulin, and plasmapheresis in patients with
      hypertriglyceridemia induced moderate/severe acute pancreatitis on the course and outcome of
      disease.After acceptance patients will be randomized by random envelope in the 3 groups:
      Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin
      (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of mortality</measure>
    <time_frame>From admition to hospital discharge, an average of 2 months</time_frame>
    <description>Number of participants with fatal outcome during hospitalisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of organ failure</measure>
    <time_frame>From admition to hospital discharge, an average of 2 months</time_frame>
    <description>reanl failure, respiratory failure, circulatory failure etal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>triglyceride levels</measure>
    <time_frame>From admition to hospital discharge, an average of 2 months</time_frame>
    <description>triglyceride levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokines in serum, urine</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>IL-6, IL-8, IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dose</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Score in CT scan</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>CT Balthazar score/grade or MCTSI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α in serum, urine</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>BISAP score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Genomics</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>cfDNA et.al.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>Ranson score</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>Apache2</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Group A: intensive insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: standard insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: plasmapheresis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: plasmapheresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.
Insulin was injected by insulin pump.</description>
    <arm_group_label>Group A: intensive insulin</arm_group_label>
    <arm_group_label>Group B: standard insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>plasmapheresis</intervention_name>
    <description>Triglyceridemia should be less than 5.65 mmol/l.</description>
    <arm_group_label>Group C: plasmapheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hypertriglyceridemia induced acute pancreatitis (AP): Typical pain
             increase in serum lipase or amylase with serum TG&gt; 1,000 mg/dL (11.3mmol/L) or serum
             was milky with serum TG&gt; 500 mg/dL(5.65 mmol/L)

          -  Onset of abdominal pain within &lt;=24h before admission

          -  moderate severe or severe Acute Pancreatitis according to Atlanta criteria

          -  except for other AP causes, such as cholelithiasis, alcohol, drugs and so on

        Exclusion Criteria:

          -  other etiologies other than hyperlipidemia leading to AP

          -  at the same time combined with other etiologies of AP

          -  appear difficult to reverse respiratory failure, severe systemic circulatory failure,
             coma and other the endangered symptoms, patients expected to die within 24 hours

          -  disseminated intravascular coagulation, or patients with severe active bleeding

          -  without informed consent, the patient refused to plasma replacement, and other
             circumstances may bring significant bias.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng-Tao Zhou, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KeQing Shi, M.D.</last_name>
    <phone>(086)15858515296</phone>
    <email>skochilly@163.com</email>
  </overall_contact>
  <reference>
    <citation>Lutfi R, Huang J, Wong HR. Plasmapheresis to treat hypertriglyceridemia in a child with diabetic ketoacidosis and pancreatitis. Pediatrics. 2012 Jan;129(1):e195-8. doi: 10.1542/peds.2011-0217. Epub 2011 Dec 26.</citation>
    <PMID>22201145</PMID>
  </reference>
  <reference>
    <citation>Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009 Apr;104(4):984-91. doi: 10.1038/ajg.2009.27. Epub 2009 Mar 17. Review.</citation>
    <PMID>19293788</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Wenzhou Medical Univeristy</investigator_affiliation>
    <investigator_full_name>Meng-Tao Zhou</investigator_full_name>
    <investigator_title>The director of the department of pancreatitis; the president of First Affiliated Hospital of Wenzhou Medical Univeristy</investigator_title>
  </responsible_party>
  <keyword>hyperlipidaemic pancreatitis</keyword>
  <keyword>Plasmapheresis</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

